AR and hepatocellular carcinoma: In hepatocellular carcinoma and prostate cancer, CaMKK2 served as an attractive drug target downstream of AR, downregulation of CaMKK2 could eliminate tumor growth and inhibit macrophage-mediated inflammation [24].